Anti-MUC1 monoclonal antibody - OncoQuest

Drug Profile

Anti-MUC1 monoclonal antibody - OncoQuest

Alternative Names: Anti-MUC1 AR20.5; Anti-MUC1 mAb - Quest PharmaTech; AR20.5; BrevaRex; mAb-AR20.5

Latest Information Update: 28 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AltaRex
  • Developer OncoQuest; OncoVent; ViRexx Medical Corp
  • Class Monoclonal antibodies
  • Mechanism of Action Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • No development reported Cancer
  • Discontinued Breast cancer; Multiple myeloma

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV, Infusion)
  • 02 Nov 2016 Clinical trials in Pancreatic cancer in China (IV)
  • 02 Nov 2016 OncoVent plans a clinical trial for Pancreatic cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top